MAPT and Alzheimer disease: Hulstaert et al. reported that combined assessment with CSF Aβ42 and tau significantly improved the discrimination of Alzheimer’s disease patients from the controls and other neurologic disorders (sensitivity of 85% and specificity of 86%) [35] (Table 1).